CN116076776A - Electronic cigarette atomized liquid with monoamine oxidase activity inhibiting effect - Google Patents

Abstract

The invention relates to an electronic cigarette atomized liquid with monoamine oxidase activity inhibiting effect, which comprises the following preparation components in parts by weight: 1 to 5 parts of limonene, 1 to 5 parts of linalool, 1 to 5 parts of vanillin, 0.3 to 3 parts of phyllitol, 0.3 to 3 parts of geraniol, 1 to 5 parts of methyl cinnamate, 1 to 5 parts of menthol, 1 to 5 parts of maltol, 1 to 5 parts of benzoic acid, 1 to 5 parts of salvianic acid, 50 to 80 parts of propylene glycol and 10 to 30 parts of glycerin. The electronic cigarette atomized liquid has the beneficial effects that the electronic cigarette atomized liquid has the effect of inhibiting monoamine oxidase, solves the problem that a great amount of absorbed electronic smoke can reach a satisfactory degree due to insufficient activity of the nicotine-containing electronic cigarette atomized liquid on the market at present, solves the problem of addiction finally, gradually achieves the effect of stopping smoking, and simultaneously has the effects of increasing the memory of monoamine oxidase inhibitor, improving thinking, resisting anxiety and resisting depression.

Description

E-cigarette liquid with the effect of inhibiting the activity of monoamine oxidase

technical field

The invention belongs to the technical field of preparation of electronic smog liquid, in particular to an electronic smog liquid capable of inhibiting the activity of monoamine oxidase.

Background technique

Monoamine oxidase (MAO) is a naturally occurring enzyme in the human body, which is divided into monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B). MAO catalyzes the dehydrogenation reaction of oxidized monoamines to produce hydrogen peroxide, ammonia and aldehydes, and these products are closely related to the oxidation of cells. Monoamine oxidase is widely found in nerve and non-nerve tissues, and the monoamine oxidase in the cytoplasm of neurons is located in the outer mitochondrial membrane. Monoamine oxidase-A in the brain is mainly expressed in norepinephrine (NE) and dopamine (DA) neurons, while monoamine oxidase-B is mainly expressed in 5-hydroxytryptamine (5-HT) neurons and histaminergic neurons. Yuan and glial cells. In vivo, MAO-A has a greater affinity for 5-HT and NE, while MAO-B mainly degrades DA and phenethylamine, and inhibiting monoamine oxidase can enhance the signal transmission of monoamine transmitters. MAO-A inhibitory drugs refer to a class of drugs that can selectively inhibit MAO-A, and are mainly used for the treatment of depression. NE degradation, while increasing the concentration of 5-HT and NE in the brain synaptic cleft, play an antidepressant effect.

Studies have shown that the relationship between monoamine oxidase activity and neurotransmitter levels has been confirmed to be relevant to neurological and psychiatric diseases, and monoamine oxidase has become a valuable therapeutic target in neuropharmacology. Monoamine oxidase-A inhibitors are currently used to treat anxiety and depression. levels of norepinephrine, dopamine, and serotonin) are regulated in the brain. The monoamine transmitter imbalance hypothesis is widely recognized as the pathogenesis of depression. In patients with depression, the reduction of norepinephrine and 5-hydroxytryptamine levels in the brain and the induction of MAO-A are the most important pathogenesis of depression. factor. In addition, depression was associated with monoamine oxidase-A functional polymorphism gene and serotonin gene signaling pathway. In the case of depression, levels of monoamine oxidase A in the brain are increased. Therefore, traditional antidepressants inhibit monoamine oxidase A to reduce the activity of 5-HT signaling pathway and play a therapeutic effect. Monoamine oxidase-A inhibitors have been found to have antidepressant properties and have been used in the treatment of depression for more than 50 years. Since monoamine oxidase-A mainly metabolizes 5-HT and NE, inhibitors of this enzyme are mainly used in the treatment of depression. Studies have shown that monoamine oxidase inhibitors inhibit the deamination or metabolism of neurotransmitters. MAO inhibitors are also determined by their selectivity: some inhibitors selectively inhibit MAO-A (eg, moclobemide), some selectively inhibit MAO-B (eg, pagiline and selegiline), and some are nonselective (eg, phenelzine and tranicycline), which inhibit both MAO-A and MAO-B. Early MAO inhibitors inhibited MAO irreversibly, permanently inactivating the enzyme when they interacted with MAO. Later developed monoamine oxidase inhibitors, such as moclobemide, are reversible, meaning that MAO enzyme activity can be restored again when the inhibitor is dissociated from the enzyme. Although MAO-A inhibitors are a therapeutic mechanism in the treatment of psychological disorders, some adverse effects such as hepatotoxicity may occur when MAO-A inhibitors are taken in excess or in combination with other drugs, dietary supplements or botanicals , sedation, cognitive impairment, movement disorders, aggression, sexual dysfunction, drug tolerance and dependence, etc. At the same time, excessive MAO-A inhibition in the liver hinders the metabolism of dietary tyramine, eventually leading to a hypertensive crisis. Therefore, it is necessary to find natural non-toxic inhibitors to replace traditional MAO-A inhibitors.

Electronic cigarettes, namely electronic nicotine delivery system ENDS, currently because electronic cigarettes do not involve tobacco combustion, nicotine (nicotine) and other components are atomized before inhalation, compared with traditional cigarettes, non-combustion can reduce the toxicity of electronic cigarette users Substance absorption, these products are gradually accepted by the majority of smokers. However, because the nicotine in electronic cigarettes is not as good as ordinary cigarettes in suppressing emotions such as anxiety, these electronic cigarettes containing nicotine are also abused in large quantities, so that the goal of using electronic cigarettes to achieve smoking cessation cannot be achieved. Studies have shown that smokers relieve mental fatigue and control anxiety are related to the monoamine oxidase (MAO) inhibitor contained in cigarette smoke, but this MAO inhibitor has nothing to do with nicotine, it is caused by β-carbolines, so after smoking , this kind of cigarette smoke can relieve the anxiety of the smoker, but the e-cigarette liquid does not contain these substances, and the effect that the smoker wants cannot be achieved. The amount of smoke is more likely to lead to abuse and addiction. Recent studies have shown that nicotine has the effect of inhibiting the activity of MAO-B pure protein [Xu Jiajia, Research on the inhibition of monoamine oxidase B activity by nicotine and its anti-Parkinson's disease effect, China Tobacco Journal, 2021, 27(3): 88], but Whether nicotine also has an inhibitory effect on monoamine oxidase A has not been reported yet. Here we observe the relative abuse of cigarette smoke and e-cigarette aerosol extracts containing nicotine and a range of non-nicotine components to nicotine alone (NRT analogues) using intracranial self-stimulation (ICSS) in rats. tendency. Looking at the effects of these agents on brain MAO activity in vitro and ex vivo, the researchers also investigated the potential role of monoamine oxidase inhibition in intracranial self-stimulation studies. The researchers observed that cigarette smoke extracts contained higher levels of several non-nicotine components (eg, β-carbolines norharmane and harmane) with monoamine oxidase-inhibiting activity compared with e-cigarette extracts. Nicotine alone lowers the threshold of intracranial self-stimulation at moderate nicotine doses, suggesting a reinforcing potentiating effect that may promote abuse propensity, whereas it increases threshold of intracranial self-stimulation at high nicotine doses, suggesting aversion that may limit abuse propensity / Pleasure effect. At high nicotine doses, cigarette smoke extracts increased intracranial self-stimulation thresholds to a greater extent than nicotine alone. E-cigarette extracts had no different effects on intracranial self-stimulation than nicotine alone. The researchers observed that cigarette smoke extract significantly inhibited MAO-A and MAO-B activity in vitro, while e-cigarette extract and nicotine alone did not. [Andrew C Harris, Cigarette Smoke Extract, but NotElectronic Cigarette Aerosol Extract, Inhibits Monoamine Oxidase in vitro and Produces Greater Acute Aversive/Anhedonic Effects Than Nicotine Alone on Intracranial Self-Stimulation in Rats.Front Neurosci.2022May 25;16:868088.], these The findings indicated that cigarette smoke extract had a greater acute aversive/anhedonic effect than nicotine alone, indicating a lower propensity for abuse. Although confirmation of these findings using other dosing regimens, preclinical addiction models, and tobacco product extracts is required, these findings suggest that centrally mediated effects of MAOIs and other non-nicotine ingredients are future candidates for anxiolytic efficacy Ingredients that must be added to e-cigarettes.

Contents of the invention

The purpose of the present invention is to provide an electronic smog liquid that can inhibit the activity of monoamine oxidase A. After a large number of experimental drug combinations and experimental observations, we have found an electronic smog liquid that can especially inhibit the activity of monoamine oxidase A. The atomized liquid It can maintain the characteristics and flavor of nicotine in electronic cigarettes, and also has the effect of anti-anxiety and anti-depressant monoamine oxidase A inhibitor.

The technical solution of the present invention is an electronic smog liquid with the effect of inhibiting the activity of monoamine oxidase. 0.3-3 parts of leaf alcohol, 0.3-3 parts of geraniol, 1-5 parts of methyl cinnamate, 1-5 parts of menthol, 1-5 parts of maltol, 1-5 parts of benzoic acid, 1 part of Danshensu ～5 parts, 50～80 parts of propylene glycol, 10～30 parts of glycerin.

Preferably, the preparation components further include: 0.1-5 parts of nicotine in parts by weight.

Preferably, its preparation components also include: 1-5 parts of naringin in parts by weight.

Preferably, the preparation components further include: 0.1-5 parts of nicotine and 1-5 parts of naringin in parts by weight.

Preferably, 2-4 parts of limonene, 1.2-3 parts of linalool, 1.5-3 parts of vanillin, 0.5-2 parts of leaf alcohol, 0.5-1.5 parts of geraniol, 1.2 to 2 parts of methyl cinnamate, 1 to 3 parts of menthol, 1 to 2 parts of maltol, 1 to 2 parts of benzoic acid, 1 to 2 parts of danshensu, and 1 to 2 parts of propylene glycol 71 to 78 parts, and 11 to 15 parts of glycerol.

Preferably, 2.5 parts of the limonene, 1.5 parts of the linalool, 2 parts of the vanillin, 0.5 parts of the leaf alcohol, 0.5 parts of the geraniol, 1.5 parts of the methyl cinnamate, the 1.5 parts of menthol, 1 part of maltol, 1 part of benzoic acid, 1 part of danshensu, 74.5 parts of propylene glycol, and 12.5 parts of glycerin.

Preferably, 2-4 parts of limonene, 1.2-3 parts of linalool, 1.5-3 parts of vanillin, 0.5-2 parts of leaf alcohol, 0.5-1.5 parts of geraniol, 1.2 to 2 parts of methyl cinnamate, 1 to 3 parts of menthol, 1 to 2 parts of maltol, 1 to 2 parts of benzoic acid, 1 to 2 parts of danshensu, and 1 to 2 parts of propylene glycol 71-78 parts, 11-15 parts of glycerin, and 0.2-2 parts of nicotine.

Preferably, 2.5 parts of the limonene, 1.5 parts of the linalool, 2 parts of the vanillin, 0.5 parts of the leaf alcohol, 0.5 parts of the geraniol, 1.5 parts of the methyl cinnamate, the 1.5 parts of menthol, 1 part of maltol, 1 part of benzoic acid, 1 part of danshensu, 74 parts of propylene glycol, 12.5 parts of glycerin, and 0.5 part of nicotine.

Preferably, 2-4 parts of limonene, 1.2-3 parts of linalool, 1.5-3 parts of vanillin, 0.5-2 parts of leaf alcohol, 0.5-1.5 parts of geraniol, 1.2 to 2 parts of methyl cinnamate, 1 to 3 parts of menthol, 1 to 2 parts of maltol, 1 to 2 parts of benzoic acid, 1 to 2 parts of danshensu, and 1 to 2 parts of propylene glycol 71-78 parts, 11-15 parts of glycerin, and 1-3 parts of naringin.

Preferably, 2.5 parts of the limonene, 1.5 parts of the linalool, 2 parts of the vanillin, 0.5 parts of the leaf alcohol, 0.5 parts of the geraniol, 1.5 parts of the methyl cinnamate, the 1.5 parts of menthol, 1 part of maltol, 1 part of benzoic acid, 1 part of danshensu, 74 parts of propylene glycol, 12 parts of glycerin, and 1 part of naringin.

Preferably, 2-4 parts of limonene, 1.2-3 parts of linalool, 1.5-3 parts of vanillin, 0.5-2 parts of leaf alcohol, 0.5-1.5 parts of geraniol, 1.2 to 2 parts of methyl cinnamate, 1 to 3 parts of menthol, 1 to 2 parts of maltol, 1 to 2 parts of benzoic acid, 1 to 2 parts of danshensu, and 1 to 2 parts of propylene glycol 71-78 parts, 11-15 parts of glycerin, 0.2-2 parts of nicotine, and 1-3 parts of naringin.

Preferably, 2.5 parts of the limonene, 1.5 parts of the linalool, 2 parts of the vanillin, 0.5 parts of the leaf alcohol, 0.5 parts of the geraniol, 1.5 parts of the methyl cinnamate, the 1.5 parts of menthol, 1 part of maltol, 1 part of benzoic acid, 1 part of danshensu, 73.5 parts of propylene glycol, 12 parts of glycerin, 0.5 part of nicotine, and 1 part of pomelo peel glycosides 1 part.

To sum up, compared with the prior art, the beneficial effects of the present invention are: the present invention uses danshensu and vanillin as additives to prepare the electronic smog liquid with the main effect of inhibiting the activity of monoamine oxidase, which solves the problem of containing The nicotine e-cigarette liquid inhibits the activity of monoamine oxidase due to the lack of activity and needs to absorb a large amount of e-cigarettes to achieve a satisfactory level, which solves the problem of addiction and finally achieves the effect of smoking cessation. Both the nicotine-free electronic cigarette liquid and the nicotine-containing electronic cigarette liquid provided by the present invention have the effect of significantly inhibiting monoamine oxidase, so that they can reduce the psychological stress or mental state such as tension and anxiety that smokers want after smoking. Thereby reducing the desire to continue smoking, and gradually achieve the goal of smoking cessation. In addition, the present invention also adds limonene and linalool to the solvent of the e-cigarette liquid, which can improve the taste and flavor of the e-cig liquid, especially without the feeling of dry throat, no residue accumulation, and increased flavor intensity. , also has the effects of increasing memory, improving thinking, anti-anxiety, and anti-depressant effects of monoamine oxidase inhibitors.

Detailed ways

The present invention will be described in further detail below in conjunction with embodiment:

The present invention describes an e-cigarette liquid that can inhibit the activity of monoamine oxidase, that is, in the process of preparing the e-cigarette liquid, components that have the effect of inhibiting monoamine oxidase, such as limonene, linalool, vanillin, leaf alcohol , geraniol, methyl cinnamate, menthol, maltol, benzoic acid, danshensu, naringin, etc. are added in proportion by weight.

One embodiment of the electronic smog liquid with the effect of inhibiting the activity of monoamine oxidase of the present invention is that the components for preparing the atomized liquid include by weight: 1-5 parts of limonene, 1-5 parts of linalool, 1-5 parts of vanillin 5 parts, 0.3-3 parts of leaf alcohol, 0.3-3 parts of geraniol, 1-5 parts of methyl cinnamate, 1-5 parts of menthol, 1-5 parts of maltol, 1-5 parts of benzoic acid, Danshensu 1-5 parts, 50-80 parts of propylene glycol, 10-30 parts of glycerin.

Another embodiment of the electronic smog liquid with the effect of inhibiting the activity of monoamine oxidase of the present invention is that the components for preparing the liquid include by weight: 1-5 parts of limonene, 1-5 parts of linalool, 1 part of vanillin ～5 parts, 0.3～3 parts of leaf alcohol, 0.3～3 parts of geraniol, 1～5 parts of methyl cinnamate, 1～5 parts of menthol, 1～5 parts of maltol, 1～5 parts of benzoic acid, Salvia miltiorrhiza 1 to 5 parts of vegetarian food, 50 to 80 parts of propylene glycol, 10 to 30 parts of glycerin, and 0.1 to 5 parts of nicotine.

Another embodiment of the electronic smog liquid with the effect of inhibiting the activity of monoamine oxidase of the present invention is that the components for preparing the liquid include by weight: 1-5 parts of limonene, 1-5 parts of linalool, 1 part of vanillin ～5 parts, 0.3～3 parts of leaf alcohol, 0.3～3 parts of geraniol, 1～5 parts of methyl cinnamate, 1～5 parts of menthol, 1～5 parts of maltol, 1～5 parts of benzoic acid, Salvia miltiorrhiza 1 to 5 parts of vegetable oil, 50 to 80 parts of propylene glycol, 10 to 30 parts of glycerin, and 1 to 5 parts of naringin.

Another embodiment of the electronic smog liquid with the effect of inhibiting the activity of monoamine oxidase of the present invention is that the components for preparing the liquid include by weight: 1-5 parts of limonene, 1-5 parts of linalool, 1 part of vanillin ～5 parts, 0.3～3 parts of leaf alcohol, 0.3～3 parts of geraniol, 1～5 parts of methyl cinnamate, 1～5 parts of menthol, 1～5 parts of maltol, 1～5 parts of benzoic acid, Salvia miltiorrhiza 1 to 5 parts of vegetable oil, 50 to 80 parts of propylene glycol, 10 to 30 parts of glycerin, 0.1 to 5 parts of nicotine, and 1 to 5 parts of naringin.

Another embodiment of the electronic smog liquid with the effect of inhibiting the activity of monoamine oxidase of the present invention is that the components for preparing the liquid include by weight: 2-4 parts of limonene, 1.2-3 parts of linalool, 1.5 parts of vanillin ～3 parts, 0.5～2 parts of leaf alcohol, 0.5～1.5 parts of geraniol, 1.2～2 parts of methyl cinnamate, 1～3 parts of menthol, 1～2 parts of maltol, 1～2 parts of benzoic acid, Salvia miltiorrhiza 1-2 parts of vegetable, 71-78 parts of propylene glycol, 11-15 parts of glycerin.

Another embodiment of the electronic smog liquid with the effect of inhibiting the activity of monoamine oxidase of the present invention is that the components for preparing the liquid include by weight: 2-4 parts of limonene, 1.2-3 parts of linalool, 1.5 parts of vanillin ～3 parts, 0.5～2 parts of leaf alcohol, 0.5～1.5 parts of geraniol, 1.2～2 parts of methyl cinnamate, 1～3 parts of menthol, 1～2 parts of maltol, 1～2 parts of benzoic acid, Salvia miltiorrhiza 1 to 2 parts of vegetarian food, 71 to 78 parts of propylene glycol, 11 to 15 parts of glycerin, and 0.2 to 2 parts of nicotine.

Another embodiment of the electronic smog liquid with the effect of inhibiting the activity of monoamine oxidase of the present invention is that the components for preparing the liquid include by weight: 2-4 parts of limonene, 1.2-3 parts of linalool, 1.5 parts of vanillin ～3 parts, 0.5～2 parts of leaf alcohol, 0.5～1.5 parts of geraniol, 1.2～2 parts of methyl cinnamate, 1～3 parts of menthol, 1～2 parts of maltol, 1～2 parts of benzoic acid, Salvia miltiorrhiza 1 to 2 parts of vegetable oil, 71 to 78 parts of propylene glycol, 11 to 15 parts of glycerin, and 1 to 3 parts of naringin.

Another embodiment of the electronic smog liquid with the effect of inhibiting the activity of monoamine oxidase of the present invention is that the components for preparing the liquid include by weight: 2-4 parts of limonene, 1.2-3 parts of linalool, 1.5 parts of vanillin ～3 parts, 0.5～2 parts of leaf alcohol, 0.5～1.5 parts of geraniol, 1.2～2 parts of methyl cinnamate, 1～3 parts of menthol, 1～2 parts of maltol, 1～2 parts of benzoic acid, Salvia miltiorrhiza 1 to 2 parts of vegetable oil, 71 to 78 parts of propylene glycol, 11 to 15 parts of glycerin, 0.2 to 2 parts of nicotine, and 1 to 3 parts of naringin.

Concrete embodiments of the present invention are as follows:

Embodiment one

The nicotine-free e-cigarette liquid that has the effect of inhibiting the activity of monoamine oxidase A is called Jieyu No. 1 e-cigarette liquid, and the following components are weighed in parts by weight during preparation: 2.5 parts of limonene, 1.5 parts of linalool , 2 parts of vanillin, 0.5 parts of leaf alcohol, 0.5 parts of geraniol, 1.5 parts of methyl cinnamate, 1.5 parts of menthol, 1 part of maltol, 1 part of benzoic acid, 1 part of danshensu, 74.5 parts of propylene glycol, glycerin 12.5 parts, then mix the above-mentioned components, heat properly and dissolve fully.

Embodiment two

The nicotine-containing e-cigarette liquid that can inhibit the activity of monoamine oxidase A is called Jieyu No. 2 e-cig liquid, and the following components are weighed in parts by weight during preparation: 2.5 parts of limonene, 1.5 parts of linalool, 2 parts of vanillin, 0.5 parts of leaf alcohol, 0.5 parts of geraniol, 1.5 parts of methyl cinnamate, 1.5 parts of menthol, 1 part of maltol, 1 part of benzoic acid, 1 part of danshensu, 74 parts of propylene glycol, 12.5 parts of glycerin part, 0.5 part of nicotine, and then the above-mentioned components are mixed, properly heated and fully dissolved.

Embodiment Three

The nicotine-free e-cigarette liquid that can inhibit the activity of monoamine oxidase A is called Jieyu No. 3 e-cigarette liquid, and the following components are weighed in parts by weight during preparation: 2.5 parts of limonene, 1.5 parts of linalool , 2 parts of vanillin, 0.5 parts of leaf alcohol, 0.5 parts of geraniol, 1.5 parts of methyl cinnamate, 1.5 parts of menthol, 1 part of maltol, 1 part of benzoic acid, 1 part of danshensu, 74 parts of propylene glycol, glycerin 12 parts, 1 part of naringin, and then mix the above-mentioned components, heat properly and dissolve fully.

Embodiment four

The nicotine-containing e-cigarette liquid that can inhibit the activity of monoamine oxidase A is called Jieyu No. 4 e-cig liquid, and the following components are weighed in parts by weight during preparation: the preparation components include: limonene in parts by weight 2.5 parts, 1.5 parts of linalool, 2 parts of vanillin, 0.5 parts of leaf alcohol, 0.5 parts of geraniol, 1.5 parts of methyl cinnamate, 1.5 parts of menthol, 1 part of maltol, 1 part of benzoic acid, Danshensu 1 part, 73.5 parts of propylene glycol, 12 parts of glycerin, 0.5 part of nicotine, 1 part of naringin, and then mix the above-mentioned components, heat properly and fully dissolve.

Experimental proof

In the above embodiments and examples of the present invention, we have done a lot of experiments through the detection method of monoamine oxidase in vitro, among which, we have chosen the kit of abnova company, the instructions point out that monoamine oxidase is a mitochondrial enzyme family, which can catalyze the oxidation of monoamine Deamination. There are two isoforms of MAO, MAO-A and MAO-B, with different inhibitor selectivity and tissue distribution. MAO dysfunction is thought to be the cause of many neurological diseases. Abnormally high or low levels of MAOs in the body have been linked to depression, schizophrenia, substance abuse, attention deficit disorder, migraines, and irregular sexual maturation. MAO inhibitors are one of the main drugs in the treatment of depression, Parkinson's disease and Alzheimer's disease. The MAO inhibitor screening and detection kit provides a convenient fluorescence measurement means for screening MAO enzyme inhibitors. In the experiment, MAO reacted with p-tyramine, the substrate of MAO-A and MAO-B, to form H2O2, which was measured by fluorescence method (em/ex=585/530nm). The detection method is simple, sensitive, stable, and highly adaptable to high throughput.

Purpose of the experiment: To observe whether Jieyu No. 1, Jieyu No. 2, Jieyu No. 3 and Jieyu No. 4 proposed in Examples 1 to 4 can inhibit the activity of MAO-A.

Experimental equipment: precision electronic balance, weighing paper, weighing spoon, 0.2-2ul pipette gun, 0.5-10ul pipette gun, 10-100ul pipette gun, 20-200ul pipette gun, 100-1000ul pipette gun, 1.5ml EP tube, 10ml EP tube, water bath, black 96-well plate, incubator, timer, multifunctional microplate detection system, Monoamine Oxidase Inhibitor Screening Assay Kit, MAO-A.

Experimental principle: use the fluorescence method (EM/EX=585/530nm) to measure the reaction of MAO with the substrates of MAO-A and MAO-B to tyramine to generate H2O2. Using the calculation formula: MAO Activity%=[(RFUTest Cpd-RFUBlank)/(RFUNoInhibitor-RFUBlank)]*100%, calculate the activities of MAO, MAO-A and MAO-B. The method is simple, sensitive, stable and adaptable.

experimental method

1. Preparation of Drugs for Experimental Study

Experimental drugs and formulations are shown in Table 1:

Table 1: E-cigarette liquid formulations with the effect of inhibiting the activity of monoamine oxidase

2. Dilution of MAO-A: Take 4ul of 345U/ml MAO-A and add DH2O 456ul to dilute and purify MAO-A to 3U/ml;

3. Operate according to the instructions of Monoamine Oxidase Inhibitor Screening Assay Kit:

(1) Dilution of positive control drug (monoamine oxidase A inhibitor clorgyline): take 20mMclorgyline 1ul and add DH2O 2ml to dilute to 10uM clorgyline;

(2) The experiment set up a blank group, a control group, an inhibitor group, Jieyu No. 1, Jieyu No. 2, Jieyu No. 3 and Jieyu No. 4, and the experiment was performed twice in parallel;

(3) Add in sequence to the black 96-well plate:

Blank group: 45ul MAO-A 5ul propylene glycol: glycerol = 6:1 Control group: 45ul MAO-A 5ul propylene glycol: glycerol = 6:1 Inhibitors: 45ul MAO-A 5ul 10uM clorgyline Drug 1: 45ul MAO-A 5ul Jieyu No.1 Drug 2: 45ul MAO-A 5ul Jieyu No. 2 Drug 3: 45ul MAO-A 5ul Jieyu No.3 Drug 4: 45ul MAO-A 5ul Jieyu No.4

(4) Put the black 96-well plate in a 25°C incubator for 15 minutes;

(5) Preparation of substrate (P-Tyramme): Take 8ul of P-Tyramme and add DH2O 4ul to make 1.5 times P-Tyramme;

(6) Preparation of blank working solution and working solution:

(7) Add 50ul blank working solution to the blank group, add 50ul working solution to the other groups, react for 20min under dark conditions, and read the fluorescence intensity at EM/EX=585/530nm.

(8) According to the formula, calculate the activity of MAO-A of drug 1 group, drug 2 group, drug 3 group and drug 4 group.

4. Experimental data recording:

The experimental results are shown in Table 2:

Table 2: Experimental results of experimental drugs in each group

Experimental results: blank group control group Inhibitor drug 1 drug 2 1 hole 18890 472398 16334 213902 111375 2 holes 18014 491319 15226 219780 120950 average 18452 481858.5 15780 216841 116162.5

5. The inhibitory activity of each group of experimental drugs on monoamine oxidase:

The active effects of each experimental drug on monoamine oxidase are shown in Table 3:

Table 3: The effect of each experimental drug on the activity of monoamine oxidase

Test data standard data Enzyme activity Inhibition rate control group 481858.5 463406.5 100.00% 0 Inhibitor 15780 -2672 -0.58% 100.58% Jieyu No.1 216841 198389 42.81% 57.19% Jie Yu No. 2 116162.5 97710.5 21.09% 78.91% Jieyu No.3 238683.5 220231.5 47.52% 52.48% Jieyu No.4 95680 77228 16.67% 83.33%

6. Experimental conclusion:

In this experiment, monoamine oxidase A was used to observe the activity. The activity of the control group in this experiment was 100%, and the activity of positive control drug monoamine oxidase A inhibitor clorgyline was -0.58%, that is, the enzyme inhibition rate also reached 100.58%; the MAO-A activity of Jieyu No. 1 was 42.81%, and its enzyme inhibition rate was 57.19%. The MAO-A activity of Jieyu No. 2 was 21.09%; MAO-A activity was 47.52%; its enzyme inhibition rate was 52.48%, MAO-A activity of Jieyu 4 was 16.67%; its enzyme inhibition rate was 83.33%. The results of the study showed that the four observed drugs all had the effect of inhibiting the activity of monoamine oxidase A, and Jieyu No. 4 and Jieyu No. 2 were better at inhibiting the activity of monoamine oxidase A. The formulas of these two preparations both contained nicotine. It is suggested that the prescription containing nicotine has a stronger inhibitory ability to the activity of monoamine oxidase-A.

The electronic smog liquid formulated according to the technical scheme of the embodiment of the present invention meets the quality requirements of the electronic smog liquid through pharmacy testing. Through animal experiment observation, mice continuously inhale the electronic smog liquid of the present invention for 2 months, every day One time, 2 hours each time, no toxic reaction was found, and no pathological changes were found in the pathological examination of the heart, lung and brain tissues. Studies have shown that the electronic cigarette liquid prepared by the technical solution of the present invention will not cause toxicity to mice who smoke continuously for 2 months.

The above descriptions are only preferred embodiments of the present invention, and all equivalent changes and modifications made according to the scope of the claims of the present invention shall fall within the scope of the claims of the present invention.

Claims (12)

1. The electronic cigarette atomized liquid with the monoamine oxidase activity inhibiting effect is characterized by comprising the following preparation components in parts by weight: 1 to 5 parts of limonene, 1 to 5 parts of linalool, 1 to 5 parts of vanillin, 0.3 to 3 parts of phyllitol, 0.3 to 3 parts of geraniol, 1 to 5 parts of methyl cinnamate, 1 to 5 parts of menthol, 1 to 5 parts of maltol, 1 to 5 parts of benzoic acid, 1 to 5 parts of salvianic acid, 50 to 80 parts of propylene glycol and 10 to 30 parts of glycerin.

2. The electronic cigarette atomized liquid with monoamine oxidase activity inhibiting effect according to claim 1, wherein the preparation components of the electronic cigarette atomized liquid comprise the following components in parts by weight: 0.1 to 5 portions of nicotine.

3. The electronic cigarette atomized liquid with monoamine oxidase activity inhibiting effect according to claim 1, wherein the preparation components of the electronic cigarette atomized liquid comprise the following components in parts by weight: 1-5 parts of naringin.

4. The electronic cigarette atomized liquid with monoamine oxidase activity inhibiting effect according to claim 1, wherein the preparation components of the electronic cigarette atomized liquid comprise the following components in parts by weight: 0.1 to 5 portions of nicotine and 1 to 5 portions of naringin.

5. The electronic cigarette atomized liquid with monoamine oxidase activity inhibiting effect according to claim 1, wherein 2-4 parts of limonene, 1.2-3 parts of linalool, 1.5-3 parts of vanillin, 0.5-2 parts of phyllitol, 0.5-1.5 parts of geraniol, 1.2-2 parts of methyl cinnamate, 1-3 parts of menthol, 1-2 parts of maltol, 1-2 parts of benzoic acid, 1-2 parts of tanshinol, 71-78 parts of propylene glycol and 11-15 parts of glycerin.

6. The electronic cigarette atomized liquid with monoamine oxidase activity inhibiting effect according to claim 5, wherein 2.5 parts of limonene, 1.5 parts of linalool, 2 parts of vanillin, 0.5 parts of phyllitol, 0.5 parts of geraniol, 1.5 parts of methyl cinnamate, 1.5 parts of menthol, 1 part of maltol, 1 part of benzoic acid, 1 part of salvianic acid, 74.5 parts of propylene glycol and 12.5 parts of glycerin.

7. The electronic cigarette atomized liquid with monoamine oxidase activity inhibiting effect according to claim 2, wherein 2-4 parts of limonene, 1.2-3 parts of linalool, 1.5-3 parts of vanillin, 0.5-2 parts of phyllitol, 0.5-1.5 parts of geraniol, 1.2-2 parts of methyl cinnamate, 1-3 parts of menthol, 1-2 parts of maltol, 1-2 parts of benzoic acid, 1-2 parts of tanshinol, 71-78 parts of propylene glycol, 11-15 parts of glycerin and 0.2-2 parts of nicotine.

8. The electronic cigarette atomized liquid with monoamine oxidase activity inhibiting effect according to claim 7, wherein 2.5 parts of limonene, 1.5 parts of linalool, 2 parts of vanillin, 0.5 parts of phyllitol, 0.5 parts of geraniol, 1.5 parts of methyl cinnamate, 1.5 parts of menthol, 1 part of maltol, 1 part of benzoic acid, 1 part of salvianic acid, 74 parts of propylene glycol, 12.5 parts of glycerin and 0.5 part of nicotine.

9. The electronic cigarette atomized liquid with monoamine oxidase activity inhibiting effect according to claim 3, wherein 2-4 parts of limonene, 1.2-3 parts of linalool, 1.5-3 parts of vanillin, 0.5-2 parts of phyllitol, 0.5-1.5 parts of geraniol, 1.2-2 parts of methyl cinnamate, 1-3 parts of menthol, 1-2 parts of maltol, 1-2 parts of benzoic acid, 1-2 parts of tanshinol, 71-78 parts of propylene glycol, 11-15 parts of glycerin and 1-3 parts of naringin.

10. The electronic cigarette atomized liquid with monoamine oxidase activity inhibiting effect according to claim 9, wherein 2.5 parts of limonene, 1.5 parts of linalool, 2 parts of vanillin, 0.5 parts of phyllitol, 0.5 parts of geraniol, 1.5 parts of methyl cinnamate, 1.5 parts of menthol, 1 part of maltol, 1 part of benzoic acid, 1 part of salvianic acid, 74 parts of propylene glycol, 12 parts of glycerin and 1 part of naringin.

11. The electronic cigarette atomized liquid with monoamine oxidase activity inhibiting effect according to claim 4, wherein 2-4 parts of limonene, 1.2-3 parts of linalool, 1.5-3 parts of vanillin, 0.5-2 parts of phyllitol, 0.5-1.5 parts of geraniol, 1.2-2 parts of methyl cinnamate, 1-3 parts of menthol, 1-2 parts of maltol, 1-2 parts of benzoic acid, 1-2 parts of tanshinol, 71-78 parts of propylene glycol, 11-15 parts of glycerin, 0.2-2 parts of nicotine and 1-3 parts of naringin.

12. The electronic cigarette atomized liquid having a monoamine oxidase inhibitory action according to claim 11, wherein 2.5 parts of limonene, 1.5 parts of linalool, 2 parts of vanillin, 0.5 parts of phyllitol, 0.5 parts of geraniol, 1.5 parts of methyl cinnamate, 1.5 parts of menthol, 1 part of maltol, 1 part of benzoic acid, 1 part of salvianic acid, 73.5 parts of propylene glycol, 12 parts of glycerin, 0.5 parts of nicotine and 1 part of naringin.